Biogen CEO hails quartet of new launches as multiple sclerosis competition weighs on 2025 guidance
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to be sitting well with investors, company leadership remains confident that a crop of new drugs can pick up the slack in the months and years to come.
Biogen expects 2025 profit decline despite strong Q4
American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this, the company beat fourth quarter expectations — driven by cost-cutting and new product launches,
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...
2don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...
Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback